Sonoma Pharmaceuticals AI Stock Analysis
Want to see SNOA full AI Analyst Report?
Sonoma Pharmaceuticals (SNOA) AI Stock Analysis
Sonoma Pharmaceuticals
(NASDAQ:SNOA)
The overall score of 48 reflects a high-risk, early-stage turnaround situation. The company's primary strength is its debt-free balance sheet, which provides a crucial runway. However, this is overshadowed by the core weaknesses of deep unprofitability and ongoing cash burn, which are reflected in a very poor valuation. Positive technical momentum and a prudent corporate event to protect tax assets provide minor offsets.
Sonoma Pharmaceuticals Key Performance Indicators (KPIs)
Revenue by SegmentBreaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.
Human Care has become the clear growth engine, delivering a step‑change in 2024–26 and driving most of the company’s revenue upside; Animal Care is flat and not keeping pace, suggesting limited diversification. The abrupt disappearance of the “Other” line after mid‑2025 looks like a divestiture or reclassification, concentrating risk in Human Care. For investors, sustainability of Human Care’s gains (organic demand, pricing, or M&A) and margin impact are the key items to watch.
The FlySonoma Pharmaceuticals (SNOA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 59.27K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 2.06
- Revenue Growth
- 38.69%
- EPS Growth
- 58.68%
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Sonoma Pharmaceuticals Business Overview & Revenue Model
Company Description
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygien...
How the Company Makes Money
Sonoma Pharmaceuticals primarily makes money by selling Microcyn-based products and related topical/wound-care solutions through (1) product revenue from commercial sales (sold either directly by Sonoma in certain geographies/channels or via distribu...
Sonoma Pharmaceuticals Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a clear strength with minimal debt, providing stability. However, persistent operating losses and negative cash flow, despite improving trends, remain significant weaknesses that heavily weigh on the overall score.
Income Statement
35NegativeBalance Sheet
72PositiveCash Flow
30Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.49M | 19.53M | 14.29M | 12.73M | 13.27M | 12.63M |
| Gross Profit | 9.21M | 7.42M | 5.46M | 4.75M | 4.48M | 3.99M |
| EBITDA | -878.00K | -2.32M | -2.77M | -4.86M | -5.06M | -5.22M |
| Net Income | -1.80M | -3.17M | -3.46M | -4.83M | -5.15M | -5.09M |
Balance Sheet | ||||||
| Total Assets | 17.10M | 13.96M | 13.69M | 14.74M | 16.23M | 18.84M |
| Cash, Cash Equivalents and Short-Term Investments | 4.61M | 2.40M | 5.37M | 3.13M | 3.82M | 7.40M |
| Total Debt | 602.00K | 842.00K | 305.00K | 608.00K | 849.00K | 1.37M |
| Total Liabilities | 10.49M | 10.87M | 9.28M | 8.60M | 8.25M | 10.15M |
| Stockholders Equity | 6.61M | 3.10M | 4.41M | 6.14M | 7.98M | 8.70M |
Cash Flow | ||||||
| Free Cash Flow | -2.79M | -4.13M | -168.00K | -2.42M | -6.42M | -4.38M |
| Operating Cash Flow | -2.67M | -3.93M | -88.00K | -2.40M | -6.15M | -4.25M |
| Investing Cash Flow | -120.00K | -192.00K | -80.00K | -2,000 | -258.00K | -99.00K |
| Financing Cash Flow | 4.28M | 477.00K | 3.03M | 1.68M | 2.49M | 7.40M |
Sonoma Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.21, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.97 is Neutral, neither overbought nor oversold. The STOCH value of 61.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SNOA.
Sonoma Pharmaceuticals Risk Analysis
Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSonoma Pharmaceuticals Peers Comparison
Overall Rating
AMRX58Neutral
PRGO52Neutral- SNOA48Neutral
AQST47Neutral
DERM46Neutral
ORGO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AMRX | 58Neutral | $7.56B | 50.14 | 131.71% | ― | 8.88% | 2272.07% |
| PRGO | 52Neutral | $2.30B | -1.27 | -68.13% | 7.17% | -4.45% | -3289.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SNOA | 48Neutral | $6.28M | -1.27 | -36.40% | ― | 38.69% | 58.68% |
| AQST | 47Neutral | $449.96M | -5.59 | 255.11% | ― | 12.54% | 8.82% |
| DERM | 46Neutral | $125.32M | -19.61 | -20.23% | ― | 20.89% | 40.71% |
| ORGO | 39Underperform | $136.29M | -0.82 | -46.25% | ― | -24.33% | -1171.44% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SNOA | Sonoma Pharmaceuticals, Inc. | 1.17 | -2.27 | -65.99% | |
| PRGO | Perrigo Company | 16.18 | 3.59 | 28.49% | |
| ORGO | Organogenesis Holdings | 0.96 | -5.13 | -84.18% | |
| AMRX | Amneal Pharma | 21.70 | 10.06 | 86.43% | |
| AQST | Aquestive Therapeutics, Inc. | 3.57 | -1.82 | -33.77% | |
| DERM | Journey Medical Corporation | 4.39 | -3.50 | -44.36% |
Sonoma Pharmaceuticals Corporate Events
Sonoma Pharmaceuticals Adopts New Tax-Protection Rights Plan
PositiveOn October 6, 2026, Sonoma Pharmaceuticals’ board approved a new Section 382 rights agreement with Computershare Inc., effective immediately and replacing a prior plan that was due to expire on October 18, 2026. The agreement establishes a dividend o...
Sonoma Pharmaceuticals Announces Results of Annual Shareholder Meeting
NeutralSonoma Pharmaceuticals held its annual meeting of stockholders on September 16, 2026, with 2,082,799 shares of common stock present or represented by valid proxy out of 4,788,425 shares entitled to vote. Each share carried one vote, underscoring the...
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting
NegativeOn August 19, 2026, Sonoma Pharmaceuticals, Inc. convened an adjourned special meeting of stockholders that had been called pursuant to a proxy process initiated in early May 2026. The meeting covered 3,473,554 eligible common shares, but a quorum of...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026